GO:1903707 negative regulation of hemopoiesis: Regulatory Mechanisms, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1903707 describes any biological process that stops, prevents, or reduces the frequency, rate, or extent of hemopoiesis, the formation of blood cellular components.
• Negative regulation of hemopoiesis is essential for balancing blood cell production, preventing hematopoietic malignancies, and maintaining immune homeostasis.
• Key negative regulators include WNT signaling components, JAK/STAT inhibitors such as SOCS proteins, p53, activin A, and latexin.
• Dysregulation of this process is linked to bone marrow failure, leukemia, myeloproliferative neoplasms, and anemia.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable precise dissection of negative regulatory circuits in hematopoietic stem and progenitor cells.
• Understanding GO:1903707 provides a foundation for developing targeted therapies that modulate blood cell production in disease.
Description
Hemopoiesis, the lifelong production of all blood cell lineages from hematopoietic stem cells, is tightly controlled by positive and negative regulatory signals. The Gene Ontology term GO:1903707, negative regulation of hemopoiesis, captures the biological processes that restrain or suppress this production, ensuring that blood cell numbers remain within physiological limits and that inappropriate expansion of progenitor cells is prevented. This term is critical for researchers because imbalances in negative regulation underlie a spectrum of hematological disorders, including bone marrow failure, leukemia, and myeloproliferative neoplasms. Understanding the molecular players that execute negative regulation of hemopoiesis is therefore central to both basic hematology and therapeutic development.
negative regulation of hemopoiesis At A Glance
| GO ID | GO:1903707 |
|---|---|
| GO term | negative regulation of hemopoiesis |
| Ontology | biological_process |
| Definition | Any process that stops, prevents or reduces the frequency, rate or extent of hemopoiesis. |
| Synonyms | down regulation of blood cell biosynthesis; inhibition of hematopoiesis; negative regulation of haemopoiesis; downregulation of hemopoiesis; negative regulation of blood cell formation |
| Major function | Restraining blood cell production to maintain hematopoietic homeostasis and prevent malignancy. |
| Related processes | Apoptosis of hematopoietic progenitors, inhibition of JAK/STAT signaling, WNT pathway modulation, cell cycle arrest. |
| Key regulators | SOCS proteins, p53, activin A, latexin, WNT antagonists. |
| Disease relevance | Leukemia, bone marrow failure, myeloproliferative neoplasms, anemia. |
What Is GO:1903707?
According to the Gene Ontology, GO:1903707 (negative regulation of hemopoiesis) is defined as any process that stops, prevents, or reduces the frequency, rate, or extent of hemopoiesis. In other words, it encompasses all molecular and cellular events that put the brakes on the production of blood cells, whether by inhibiting stem cell self-renewal, blocking differentiation, or inducing apoptosis of hematopoietic progenitors.
Why Is negative regulation of hemopoiesis Important in Cell Biology?
Negative regulation of hemopoiesis is indispensable for normal physiology because unchecked blood cell production can lead to exhaustion of the hematopoietic stem cell pool, autoimmune reactions, or hematological cancers. This GO term provides a framework for understanding how extrinsic and intrinsic signals converge to suppress hemopoiesis, and how their failure contributes to disease.
• Maintains hematopoietic stem cell quiescence and prevents stem cell exhaustion.
• Prevents leukemogenesis by restraining aberrant proliferation of progenitor cells.
• Balances immune cell output to avoid autoimmunity and inflammation.
• Regulates red blood cell production to prevent polycythemia or anemia.
• Controls platelet production and megakaryopoiesis.
• Influences bone homeostasis through WNT signaling crosstalk.
• Provides therapeutic targets for bone marrow failure syndromes.
• Helps understand myeloproliferative neoplasms driven by loss of negative regulators.
• Guides development of CRISPR-based models to study gene function in hematopoiesis.
• Informs strategies for ex vivo expansion of hematopoietic stem cells for transplantation.
What Happens During negative regulation of hemopoiesis?
Inhibition of hematopoietic stem cell self-renewal and proliferation
In simple terms: This step puts the brakes on stem cells that would otherwise multiply indefinitely.
Negative regulation of hemopoiesis often begins at the level of hematopoietic stem cells (HSCs), where intrinsic factors such as p53 and extrinsic signals like WNT antagonists enforce quiescence and limit self-renewal divisions. p53 activation can induce cell cycle arrest or apoptosis in HSCs under stress, thereby reducing the pool of cells available for blood formation. Similarly, WNT signaling, which normally promotes HSC self-renewal, is counteracted by negative regulators that dampen the pathway, preventing excessive stem cell expansion.
Suppression of lineage-specific differentiation
In simple terms: Even if stem cells exist, this step stops them from turning into mature blood cells.
Negative regulation can block the differentiation of multipotent progenitors into specific lineages. For example, activin A has been shown to inhibit erythroid and megakaryocytic differentiation, acting as a negative regulator of hemopoiesis. Similarly, latexin, a carboxypeptidase inhibitor, negatively regulates hematopoietic stem and progenitor cell proliferation and differentiation, particularly in the myeloid lineage. These inhibitory signals ensure that lineage output matches physiological demand.
Induction of apoptosis in hematopoietic progenitors
In simple terms: This step eliminates excess or damaged blood-forming cells by programmed cell death.
Apoptosis of hematopoietic progenitors is a major mechanism of negative regulation. p53, in response to DNA damage or oncogenic stress, triggers apoptosis in progenitor cells, thereby preventing the propagation of mutated cells. This tumor-suppressive function is critical for avoiding leukemia. Additionally, cytokine withdrawal or inhibitory signals can activate intrinsic apoptotic pathways in progenitors, reducing blood cell output.
Negative feedback via JAK/STAT inhibitors
In simple terms: This step uses intracellular brakes to shut down growth factor signals that drive blood cell production.
The JAK/STAT pathway is a central driver of hemopoiesis in response to cytokines such as erythropoietin and granulocyte colony-stimulating factor. Negative regulation of hemopoiesis is mediated in part by suppressors of cytokine signaling (SOCS) proteins, which inhibit JAK/STAT signaling and thus dampen blood cell production. This feedback loop prevents excessive expansion of hematopoietic cells in response to cytokines.
Regulation by transcription factors and epigenetic modifiers
In simple terms: This step controls which genes are turned on or off to stop blood cell formation.
Transcriptional repressors and epigenetic modifiers can enforce negative regulation of hemopoiesis by silencing genes required for differentiation or proliferation. For instance, enhancer landscapes in hematopoiesis are cell-state-specific, and alterations in these regulatory elements can lead to loss of negative control. The balance between activating and repressive transcription factors determines whether hemopoiesis proceeds or is halted.
Key Genes Involved in GO:1903707 negative regulation of hemopoiesis
The following genes and proteins are established negative regulators of hemopoiesis, based on published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TP53 | Induces cell cycle arrest and apoptosis in hematopoietic progenitors under stress | Tumor suppression in leukemia; regulation of HSC quiescence |
| SOCS1 | Inhibits JAK/STAT signaling to dampen cytokine-driven hemopoiesis | Negative feedback in inflammation and myeloproliferation |
| SOCS3 | Suppresses JAK/STAT signaling in hematopoietic cells | Regulation of granulopoiesis and erythropoiesis |
| INHBA | Activin A subunit; inhibits erythroid and megakaryocytic differentiation | Negative regulation of hemopoiesis in anemia and bone marrow failure |
| LXN | Latexin; carboxypeptidase inhibitor that restricts HSC proliferation | Regulation of HSC pool size and myeloid output |
| DKK1 | WNT antagonist; inhibits HSC self-renewal | Bone homeostasis and hematopoietic stem cell regulation |
| SFRP1 | Secreted Frizzled-related protein; WNT antagonist | Modulates WNT signaling in hematopoiesis |
| GSK3B | Kinase that promotes beta-catenin degradation, inhibiting WNT signaling | Negative regulation of HSC self-renewal |
| CDKN1A | p21; cell cycle inhibitor downstream of p53 | Induces quiescence in hematopoietic stem cells |
| CDKN2A | p16; cell cycle inhibitor | Restrains progenitor proliferation; tumor suppressor |
| CISH | Cytokine-inducible SH2-containing protein; inhibits STAT5 | Negative regulation of cytokine signaling in hemopoiesis |
| PIAS1 | Protein inhibitor of activated STAT; blocks STAT transcriptional activity | Modulates JAK/STAT-driven hemopoiesis |
| PTPN11 | SHP-2 phosphatase; can negatively regulate cytokine signaling | Mutations cause Noonan syndrome and leukemia |
| FOXO3 | Transcription factor that promotes quiescence and stress resistance in HSCs | Negative regulation of HSC activation |
| TGFB1 | TGF-beta; inhibits proliferation of hematopoietic progenitors | Negative regulation of hemopoiesis in bone marrow niche |
| ID1 | Inhibitor of DNA binding; blocks differentiation | Regulation of lineage commitment |
| GATA2 | Transcription factor with context-dependent inhibitory roles | Fine-tuning of hematopoietic gene expression |
How Is negative regulation of hemopoiesis Regulated?
Negative regulation of hemopoiesis is itself tightly regulated at multiple levels. Cytokine signaling through JAK/STAT is controlled by SOCS proteins and phosphatases, which provide rapid negative feedback. WNT signaling is modulated by secreted antagonists such as DKK1 and SFRP1, as well as intracellular kinases like GSK3B. p53 activity is regulated by post-translational modifications and its downstream targets, including p21, which enforce cell cycle arrest. Additionally, activin A and TGF-beta family members can inhibit progenitor proliferation through SMAD-dependent pathways. Latexin provides another layer of regulation by inhibiting carboxypeptidases that would otherwise promote hematopoietic cell proliferation.
negative regulation of hemopoiesis and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| TP53 | Leukemia, bone marrow failure | TP53 knockout or point mutation in HSCs |
| SOCS1 | Myeloproliferative neoplasms, inflammation | SOCS1 knockout mice or cell lines |
| INHBA | Anemia, bone marrow failure | INHBA overexpression or knockout in erythroid progenitors |
| LXN | Hematopoietic stem cell exhaustion | Lxn knockout mouse models |
| DKK1 | Osteoporosis, hematopoietic defects | DKK1 transgenic or knockout models |
Leukemia and myeloproliferative neoplasms
Loss of negative regulation of hemopoiesis is a hallmark of hematological malignancies. In leukemia, mutations that inactivate p53 or SOCS proteins lead to uncontrolled proliferation of hematopoietic progenitors. Myeloproliferative neoplasms often arise from constitutive activation of JAK/STAT signaling due to loss of SOCS-mediated negative feedback. Restoring negative regulatory mechanisms is therefore a therapeutic goal.
Bone marrow failure syndromes
Excessive negative regulation can lead to bone marrow failure, where insufficient blood cells are produced. For example, overactive p53 or activin A signaling can suppress HSC function and contribute to aplastic anemia or myelodysplastic syndromes. Understanding the balance is critical for treating these conditions.
Anemia and erythroid disorders
Negative regulators of erythropoiesis, such as activin A, can contribute to anemia of inflammation or chronic disease by inhibiting red blood cell production. Targeting these pathways may offer therapeutic benefit.
Bone and hematopoietic crosstalk
WNT signaling is a key negative regulator of hemopoiesis and also controls bone homeostasis. Dysregulation of WNT antagonists like DKK1 can lead to both skeletal and hematopoietic abnormalities.
From negative regulation of hemopoiesis-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X negatively regulate HSC self-renewal? | Knockout of gene X in HSCs followed by serial transplantation |
| Does a point mutation in gene Y alter its inhibitory function? | Point mutation knock-in using CRISPR in hematopoietic cell lines |
| Does overexpression of gene Z suppress hemopoiesis? | Overexpression of gene Z in primary hematopoietic progenitors |
| How does a tagged version of protein W localize in hematopoietic cells? | Tagged knock-in (e.g., GFP) for imaging and co-IP |
| What is the effect of gene V loss on lineage differentiation? | Knockout of gene V in multipotent progenitors followed by colony assays |
| Can a candidate enhancer drive negative regulation? | CRISPR interference or enhancer knockout in hematopoietic cells |
How to Study the negative regulation of hemopoiesis Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global gene expression changes | Identify pathways affected by negative regulators |
| ATAC-seq | Chromatin accessibility | Map enhancers controlling hematopoietic genes |
| ChIP-seq | Transcription factor binding sites | Locate p53 or STAT binding in progenitors |
| Flow cytometry | Cell surface marker expression | Quantify HSC, progenitor, and mature cell frequencies |
| Colony-forming assay | Differentiation potential | Assess lineage output after gene manipulation |
| Western blot | Protein expression and phosphorylation | Measure JAK/STAT or WNT pathway activity |
| Proteomics | Protein abundance and interactions | Discover novel negative regulators |
| CRISPR screen | Gene function at scale | Identify negative regulators of hemopoiesis |
Transcriptomic profiling (RNA-seq)
RNA sequencing can identify genes and pathways that are differentially expressed upon manipulation of negative regulators of hemopoiesis. For example, comparing wild-type and knockout hematopoietic progenitors reveals changes in differentiation markers and cell cycle genes.
Epigenomic analysis (ATAC-seq, ChIP-seq)
Assays for chromatin accessibility and histone modifications can uncover enhancer and promoter regions that control negative regulatory genes. Cell-state-specific enhancers in hematopoiesis have been mapped using these techniques.
Flow cytometry and colony-forming assays
Flow cytometry quantifies hematopoietic stem and progenitor cell populations, while colony-forming unit assays measure their differentiation potential. These are standard for assessing negative regulation of hemopoiesis.
Proteomics and phosphoproteomics
Mass spectrometry-based proteomics can identify protein interactions and signaling changes downstream of negative regulators, such as SOCS proteins or p53.
How CRISPR Can Be Used to Study GO:1903707 negative regulation of hemopoiesis
Knockout
CRISPR knockout of candidate negative regulators in hematopoietic stem and progenitor cells allows direct testing of their role in suppressing hemopoiesis. For example, knocking out SOCS1 or TP53 can lead to increased progenitor proliferation and expansion.
Point Mutation
Point mutations can mimic disease-associated variants or disrupt specific functional domains. For instance, introducing a point mutation in the phosphatase domain of PTPN11 can reveal its role in negative regulation of cytokine signaling.
Knock-in
Knock-in of reporter tags (e.g., GFP) or epitope tags into endogenous loci enables tracking of negative regulator expression and localization in live cells. This is useful for studying dynamic changes during differentiation.
Overexpression
Overexpression of negative regulators such as LXN or INHBA can suppress hemopoiesis and provide gain-of-function models to study their inhibitory mechanisms.
How EDITGENE Supports negative regulation of hemopoiesis Research
Researchers studying negative regulation of hemopoiesis-related genes often need to determine whether a candidate gene is causally involved in suppressing blood cell production. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of hemopoiesis research.
Frequently Asked Questions About negative regulation of hemopoiesis
What is negative regulation of hemopoiesis?
Negative regulation of hemopoiesis (GO:1903707) refers to any process that stops, prevents, or reduces the frequency, rate, or extent of blood cell formation.
What genes are involved in negative regulation of hemopoiesis?
Key genes include TP53, SOCS1, SOCS3, INHBA (activin A), LXN (latexin), DKK1, and others that inhibit hematopoietic stem cell proliferation or differentiation.
How does p53 negatively regulate hemopoiesis?
p53 induces cell cycle arrest or apoptosis in hematopoietic stem and progenitor cells under stress, thereby reducing blood cell production.
What is the role of SOCS proteins in hemopoiesis?
SOCS proteins inhibit JAK/STAT signaling, providing negative feedback that dampens cytokine-driven blood cell production.
How does activin A inhibit hemopoiesis?
Activin A, encoded by INHBA, inhibits erythroid and megakaryocytic differentiation, acting as a negative regulator of hemopoiesis.
What is latexin and how does it affect hemopoiesis?
Latexin (LXN) is a carboxypeptidase inhibitor that restricts hematopoietic stem and progenitor cell proliferation, negatively regulating hemopoiesis.
What diseases are associated with defective negative regulation of hemopoiesis?
Leukemia, myeloproliferative neoplasms, bone marrow failure, and anemia can result from loss or overactivity of negative regulators.
How can CRISPR be used to study negative regulation of hemopoiesis?
CRISPR knockout, point mutation, knock-in, and overexpression models allow precise manipulation of candidate genes in hematopoietic cells to test their function.
What methods are used to study negative regulation of hemopoiesis?
Common methods include RNA-seq, ATAC-seq, flow cytometry, colony-forming assays, and proteomics.
Why is negative regulation of hemopoiesis important for bone health?
WNT signaling, which negatively regulates hemopoiesis, also controls bone homeostasis; its dysregulation can affect both blood and bone.
Conclusion
GO:1903707 negative regulation of hemopoiesis encompasses a diverse set of molecular mechanisms that restrain blood cell production, from cytokine signaling inhibitors to transcription factors and apoptosis inducers. Dysregulation of these processes contributes to hematological malignancies, bone marrow failure, and anemia, making them attractive therapeutic targets. CRISPR-based models are powerful tools to dissect these pathways and identify new regulatory nodes.
References
- 1. Baron R et al.. 2013. WNT signaling in bone homeostasis and disease: from human mutations to treatments.. Nat Med 19(2):179-92 PMID: 23389618
- 2. Barreda DR et al.. 2001. Transcriptional regulation of hemopoiesis.. Dev Comp Immunol 25(8-9):763-89 PMID: 11602195
- 3. Frömel R et al.. 2025. Design principles of cell-state-specific enhancers in hematopoiesis.. Cell 188(12):3202-3218.e21 PMID: 40345201
- 4. Caen JP et al.. 1999. Regulation of megakaryocytopoiesis.. Haemostasis 29(1):27-40 PMID: 10494032
- 5. Zhang C et al.. 2018. Latexin and hematopoiesis.. Curr Opin Hematol 25(4):266-272 PMID: 29608488
- 6. Starr R et al.. 1999. Negative regulation of the JAK/STAT pathway.. Bioessays 21(1):47-52 PMID: 10070253
- 7. Barajas S et al.. 2022. Role of p53 in regulation of hematopoiesis in health and disease.. Curr Opin Hematol 29(4):194-200 PMID: 35787548
- 8. Shav-Tal Y et al.. 2002. The role of activin a in regulation of hemopoiesis.. Stem Cells 20(6):493-500 PMID: 12456957
